MAAT.PA MaaT Pharma SA Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
17:18
Jan 06
Jan 06
MAAT Pharma GVHD approval expected in Q2.
The author states MAAT Pharma has the next microbiome drug expected to be approved in Europe in Q2 for Graft-vs-Host Disease. He argues its co-cultured microorganism ecosystem transfers a whole ecosystem rather than guessed strains, and the pipeline is at slightly later stages than competitors, with a target price three times current.
HIGH
About MAAT.PA Investor Commentary
Across the available history and selected sources, Buzzberg tracks MAAT.PA (MaaT Pharma SA) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Excellent_Notice4047.